BRII BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.27 HKD | -2.31% |
|
0.00% | -44.30% |
| May. 15 | Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China | MT |
| Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 19,309 | 4,733 | 1,512 | 859.2 | - | - |
| Enterprise Value (EV) 1 | 16,477 | 3,555 | 1,025 | 859.2 | 859.2 | 859.2 |
| P/E ratio | -2.83 x | -9.71 x | -8.63 x | -1.81 x | -3.36 x | -7.85 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 32.2 x | 3.63 x | - | 4.75 x | 2.72 x |
| EV / Revenue | - | 32.2 x | 3.63 x | - | 4.75 x | 2.72 x |
| EV / EBITDA | -4,624,273 x | -8,341,283 x | -2,586,736 x | - | - | - |
| EV / FCF | -18,870,449 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | 5.78 x | 1.48 x | 0.49 x | - | - | - |
| Nbr of stocks (in thousands) | 720,292 | 727,203 | 729,385 | 729,810 | - | - |
| Reference price 2 | 26.81 | 6.509 | 2.072 | 1.177 | 1.177 | 1.177 |
| Announcement Date | 3/22/22 | 3/24/23 | 3/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 147.2 | 416.7 | - | 180.7 | 316.2 |
| EBITDA | - | -4,176 | -567.5 | -584.3 | - | - | - |
| EBIT | - | -703 | -584.5 | -600 | - | - | - |
| Operating Margin | - | - | -397.09% | -143.97% | - | - | - |
| Earnings before Tax (EBT) | - | -4,191 | -489.8 | -184.4 | - | - | - |
| Net income 1 | -1,190 | -4,164 | -484.3 | -174.8 | -527.6 | -411.8 | -190.8 |
| Net margin | - | - | -329.03% | -41.95% | - | -227.89% | -60.34% |
| EPS 2 | -6.220 | -9.480 | -0.6700 | -0.2400 | -0.6500 | -0.3500 | -0.1500 |
| Free Cash Flow | - | -1,023 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 6/30/21 | 3/22/22 | 3/24/23 | 3/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.193 | 143 | 63.15 | 353.6 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | -347.6 | -136.7 | -189.9 | 15.09 | -121 | -125.3 | -246.3 | -134.6 | -146.7 | -281.3 |
| Net margin | -8,289.7% | -95.61% | -300.72% | 4.27% | - | - | - | - | - | - |
| EPS 2 | -0.4800 | -0.1900 | -0.2600 | 0.0200 | -0.1700 | -0.1700 | -0.3400 | -0.1800 | -0.1300 | -0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/23/22 | 3/24/23 | 8/22/23 | 3/22/24 | - | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | 2,832 | 1,178 | 486 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -1,023 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -519% | -14.8% | -5.54% | - | - | - |
| ROA (Net income/ Total Assets) | - | -171% | -13.8% | - | - | - | - |
| Assets 1 | - | 2,440 | 3,502 | - | - | - | - |
| Book Value Per Share | - | 4.640 | 4.390 | 4.220 | - | - | - |
| Cash Flow per Share | - | -2.000 | - | - | - | - | - |
| Capex | - | 1.03 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 6/30/21 | 3/22/22 | 3/24/23 | 3/22/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.177
CNY
Average target price
5.536
CNY
Spread / Average Target
+370.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.30% | 121M | |
| +12.30% | 116B | |
| +12.15% | 106B | |
| -8.14% | 23.89B | |
| -1.69% | 21.58B | |
| -10.60% | 18.96B | |
| -41.25% | 16.96B | |
| -15.33% | 16.33B | |
| +5.80% | 14.14B | |
| +28.03% | 12.02B |
- Stock Market
- Equities
- 2137 Stock
- Financials Brii Biosciences Limited
